News

Protalix Biotherapeutics (Protalix) has completed its pivotal phase III trial for prGCD, the company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

Regeneron has completed patient enrollment in two randomised, double-masked, phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet

Tobira Therapeutics (Tobira) has reported pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomised study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation

Vical has announced the results from a four-month interim analysis in an ongoing phase 2 trial for TransVax therapeutic cytomegalovirus (CMV) DNA vaccine. The results were presented at

OctoPlus has signed a pharmaceutical development and manufacturing contract with Axentis Pharma. The undisclosed contract value contributes to OctoPlus’ annual revenues, for which the company reiterates its guidance

Merck has provided new data from a phase IIB clinical study of odanacatib, oral, once-weekly investigational treatment for osteoporosis. The data showed that when stopping treatment after two

Elan has cured breach of its Tysabri collaboration agreement with Biogen that had been identified by the US District Court for the Southern District of New York. Elan’s

Abbott has received marketing authorisation from the European Commission for once-daily dosing of Kaletra (lopinavir/ritonavir) tablet, the company’s lead HIV protease inhibitor (PI), in adult patients new to

GlaxoSmithKline (GSK) has provided results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. The results demonstrate that after one dose the candidate vaccine